Cara Therapeutics Company Profile (NASDAQ:CARA)

About Cara Therapeutics (NASDAQ:CARA)

Cara Therapeutics logoCara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CARA
  • CUSIP: N/A
  • Web: www.caratherapeutics.com
Capitalization:
  • Market Cap: $403.03 million
  • Outstanding Shares: 32,581,000
Average Prices:
  • 50 Day Moving Avg: $13.39
  • 200 Day Moving Avg: $15.48
  • 52 Week Range: $5.85 - $28.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.23
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $911,000.00
  • Price / Sales: 444.55
  • Book Value: $3.35 per share
  • Price / Book: 3.71
Profitability:
  • EBITDA: ($64,690,000.00)
  • Return on Equity: -99.64%
  • Return on Assets: -85.20%
Debt:
  • Current Ratio: 16.11%
  • Quick Ratio: 16.11%
Misc:
  • Average Volume: 980,291 shs.
  • Beta: 3.08
  • Short Ratio: 13.16
 

Frequently Asked Questions for Cara Therapeutics (NASDAQ:CARA)

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.29) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.61) by $0.32. The firm's revenue was down 100.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.48) EPS. View Cara Therapeutics' Earnings History.

Where is Cara Therapeutics' stock going? Where will Cara Therapeutics' stock price be in 2017?

11 analysts have issued 12-month price targets for Cara Therapeutics' stock. Their predictions range from $20.00 to $31.50. On average, they expect Cara Therapeutics' stock price to reach $26.63 in the next twelve months. View Analyst Ratings for Cara Therapeutics.

What are analysts saying about Cara Therapeutics stock?

Here are some recent quotes from research analysts about Cara Therapeutics stock:

  • 1. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (10/4/2017)
  • 2. Needham & Company LLC analysts commented, "Cara announced outcome of planned CR845 Phase 2/3 post-surgical pain trial interim power assessment today. We spoke w/ mgmt for an update. No changes will be made to current randomization ratio across the 3 arms (1:1:1 placebo, 0.5 ug/kg, 1.0ug/kg), however target enrollment will be increased from 125/ arm to 150/ arm. Other pre-specified options were ending trial early due to low probability of success or shifting enrollment to one optimal dose. We view outcome favorably, noting that the two dose arms were evaluated independently by Data Monitoring Cmtee. Implication is that both low and high dose CR845 have potential for statistically significant effect in view of DMC. We had been concerned that low and possibly high dose evaluated in this trial may not be sufficiently high for efficacy. Mgmt guided for completing enrollment for final analysis by YE17. Separately, top-line results from CR845 Phase 2b trial in Osteoarthritis are expected later this month. We are favorably inclined based on encouraging trends in an 80-pt 2wk Phase 2a trial, but acknowledge risks tied to absence of placebo arm." (6/21/2017)
  • 3. HC Wainwright analysts commented, "CR845 as safe as placebo in respiratory safety Phase 1. Cara announced positive data this morning from a 15-patient Phase 1 trial in healthy volunteers designed to formally test for IV ‘845’s impact on respiratory drive, as respiratory depression remains one of the more severe, and potentially life-threatening, side effects of mu opioids, which ‘845 is not. The trial was a three-way crossover design utilizing the expected therapeutic dose of 1.0 ug/kg, as well as a 5.0 ug/kg supratherapeutic dose to test the upper bounds for safety. Patient respiratory drive was measured via end-tidal CO2 (ETCO2), oxygen saturation (SpO2), and respiratory rate, with primary endpoints focused on the former two. ETCO2 ranged from 36.1 to 37.8 mmHg prior to dosing, and remained well below the endpoint threshold of a 10mmHg sustained increase in ETCO2, with values of 38.1, 38.1, and 38.3 mmHg for the placebo, 1.0 ug/kg, and 5.0 ug/kg doses, respectively, one hour after administration. Both doses of ‘845 also hit on the SpO2 primary endpoint (needed to show SpO2 which did not consistently fall below 92%), with pre-treatment levels ranging from 98.3% to 98.9%, finishing an hour later at 97.8%, 98.2%, and 97.9% for the placebo,1.0 ug/kg, and 5.0 ug/kg doses, respectively. While these two primary endpoints only measured through an hour after treatment, no significant differences were seen on all three measures of respiratory drive throughout the entire 4-hour observation period of the study." (4/24/2017)
  • 4. Cantor Fitzgerald analysts commented, "The Phase 1 safety trial of IV CR845 showed no significant differences in respiratory drive vs. placebo at super-therapeutic dosing levels." (4/24/2017)
  • 5. Piper Jaffray Companies analysts commented, "Today Cara reported positive results from Part A of its Phase II/III trial for IV CR845 in uremic pruritus (UP). In our view, these results are compelling in terms of impact on worst itching scores together with more global measures of quality of life within the context of an 8-week study, as well as safety/tolerability at the go-forward doses of 0.5mcg/kg and 1.0mcg/kg. We see the robust efficacy vs safety data from this Phase II as reducing clinical risk for a broader pivotal program planned to begin by YE17. And beyond the Phase III program, we see this dataset as potentially reducing regulatory and commercial risk, and enhancing value of this asset, in the longer-term. In advance of further clinical progress in UP, including an EOP2 and Phase III start yet in '17, as well as chronic pain and post-op pain updates during 2Q17, we reiterate OW on Cara." (3/28/2017)

Who are some of Cara Therapeutics' key competitors?

Who are Cara Therapeutics' key executives?

Cara Therapeutics' management team includes the folowing people:

  • Derek T. Chalmers Ph.D., President, Chief Executive Officer, Director
  • Josef C. Schoell CPA, Chief Financial Officer
  • Frederique Menzaghi Ph.D, Vice President, Research & Development
  • Joseph William Stauffer, Chief Medical Officer
  • Harrison M. Bains Jr., Independent Director
  • Jeffrey L. Ives Ph.D., Independent Director
  • Dean Slagel, Independent Director
  • Martin A. Vogelbaum, Independent Director

How do I buy Cara Therapeutics stock?

Shares of Cara Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cara Therapeutics' stock price today?

One share of Cara Therapeutics stock can currently be purchased for approximately $12.43.


MarketBeat Community Rating for Cara Therapeutics (NASDAQ CARA)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  366 (Vote Outperform)
Underperform Votes:  150 (Vote Underperform)
Total Votes:  516
MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cara Therapeutics (NASDAQ:CARA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $26.63 (114.20% upside)
Consensus Price Target History for Cara Therapeutics (NASDAQ:CARA)
Price Target History for Cara Therapeutics (NASDAQ:CARA)
Analysts' Ratings History for Cara Therapeutics (NASDAQ:CARA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/17/2017ScotiabankBoost Price TargetOutperform$31.00 -> $31.50N/AView Rating Details
10/4/2017Needham & Company LLCReiterated RatingBuy$23.00LowView Rating Details
8/5/2017Piper Jaffray CompaniesSet Price TargetBuy$27.00HighView Rating Details
8/5/2017Canaccord GenuitySet Price TargetBuy$25.00HighView Rating Details
8/4/2017HC WainwrightReiterated RatingBuy$30.00HighView Rating Details
8/3/2017Royal Bank Of CanadaLower Price TargetOutperform$31.00 -> $29.00LowView Rating Details
8/3/2017Raymond James Financial, Inc.Lower Price TargetMarket Perform$28.00 -> $25.00LowView Rating Details
6/30/2017LaidlawLower Price TargetBuy$35.00 -> $30.00HighView Rating Details
6/30/2017Stifel NicolausReiterated RatingBuy -> Buy$24.00 -> $20.00HighView Rating Details
6/30/2017Janney Montgomery ScottDowngradeBuy -> Neutral$22.00 -> $21.00HighView Rating Details
5/19/2017Cantor FitzgeraldReiterated RatingOverweight$29.00LowView Rating Details
5/15/2017CIBCBoost Price Target$28.00 -> $29.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Cara Therapeutics (NASDAQ:CARA)
Earnings by Quarter for Cara Therapeutics (NASDAQ:CARA)
Earnings History by Quarter for Cara Therapeutics (NASDAQ CARA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.61)($0.29)$0.13 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.73)($0.81)$0.11 million$0.91 millionViewListenView Earnings Details
11/3/2016Q3($0.47)($0.42)$0.09 millionViewN/AView Earnings Details
8/4/2016Q216($0.42)($0.48)$0.13 million$0.08 millionViewN/AView Earnings Details
5/5/2016Q116($0.40)($0.39)$0.03 million$0.01 millionViewN/AView Earnings Details
3/10/2016Q4($0.33)($0.35)$0.53 millionViewListenView Earnings Details
11/9/2015Q315($0.27)($0.19)$1.86 million$2.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.24)($0.25)$0.50 million$0.87 millionViewListenView Earnings Details
5/12/2015Q415($0.22)($0.21)$0.70 million$0.50 millionViewListenView Earnings Details
3/26/2015Q4($0.28)($0.18)$1.00 million$0.91 millionViewListenView Earnings Details
11/10/2014Q314($0.22)($0.29)$0.13 million$1.13 millionViewN/AView Earnings Details
8/7/2014Q2($0.27)($0.16)$0.08 million$0.96 millionViewN/AView Earnings Details
5/12/2014Q1($0.14)($0.22)$0.30 million$0.18 millionViewN/AView Earnings Details
3/27/2014($0.18)($0.49)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cara Therapeutics (NASDAQ:CARA)
Current Year EPS Consensus Estimate: $-1.72 EPS
Next Year EPS Consensus Estimate: $-1.72 EPS

Dividends

Dividend History for Cara Therapeutics (NASDAQ:CARA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cara Therapeutics (NASDAQ:CARA)
Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 61.13%
Insider Trades by Quarter for Cara Therapeutics (NASDAQ:CARA)
Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)
Insider Trades by Quarter for Cara Therapeutics (NASDAQ:CARA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/14/2017Derek T ChalmersCEOSell25,000$15.05$376,250.00View SEC Filing  
7/14/2017Frederique Ph.D. MenzaghiVPSell3,000$15.00$45,000.00View SEC Filing  
6/29/2017Dean SlagelDirectorSell250,000$25.87$6,467,500.00View SEC Filing  
3/31/2017Ventures Vi Lp RhoMajor ShareholderBuy500,000$18.19$9,095,000.00View SEC Filing  
4/20/2016Frederique Ph.D. MenzaghiVPSell6,000$9.00$54,000.00View SEC Filing  
3/17/2016Ventures Vi Lp RhoMajor ShareholderBuy400,000$4.87$1,948,000.00View SEC Filing  
2/3/2016Frederique Ph.D. MenzaghiVPSell6,000$9.04$54,240.00View SEC Filing  
1/26/2016Michael E LewisInsiderSell7,262$10.93$79,373.66View SEC Filing  
1/6/2016Derek T ChalmersCEOSell12,500$17.22$215,250.00View SEC Filing  
12/1/2015Frederique Ph.D. MenzaghiVPSell6,000$16.21$97,260.00View SEC Filing  
11/2/2015Frederique Ph.D. MenzaghiVPSell6,000$14.26$85,560.00View SEC Filing  
10/1/2015Frederique Ph.D. MenzaghiVPSell6,000$13.95$83,700.00View SEC Filing  
9/1/2015Frederique Ph.D. MenzaghiVPSell7,000$18.63$130,410.00View SEC Filing  
8/18/2015Josef SchoellCFOBuy3,000$22.10$66,300.00View SEC Filing  
6/1/2015Michael E LewisInsiderSell7,262$9.50$68,989.00View SEC Filing  
5/19/2015Dean SlagelDirectorSell188,811$10.02$1,891,886.22View SEC Filing  
4/1/2015Michael E LewisInsiderSell7,262$9.90$71,893.80View SEC Filing  
3/2/2015Michael E LewisInsiderSell7,262$10.11$73,418.82View SEC Filing  
2/2/2015Michael E LewisInsiderSell7,262$10.60$76,977.20View SEC Filing  
2/5/2014Ventures Vi Lp RhoMajor ShareholderBuy225,818$11.00$2,483,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cara Therapeutics (NASDAQ:CARA)
Latest Headlines for Cara Therapeutics (NASDAQ:CARA)
Source:
DateHeadline
fool.com logo3 Reasons Cara Therapeutics Is a Better Growth Stock Than Novavax - Motley Fool
www.fool.com - October 20 at 3:45 AM
finance.yahoo.com logo3 Reasons Cara Therapeutics Is a Better Growth Stock Than Novavax
finance.yahoo.com - October 19 at 5:28 PM
globenewswire.com logoCara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for IV CR845 in Chronic Kidney Disease ... - GlobeNewswire (press release)
globenewswire.com - October 17 at 10:43 PM
americanbankingnews.com logoContrasting Cara Therapeutics (CARA) & Its Competitors
www.americanbankingnews.com - October 17 at 8:28 PM
finance.yahoo.com logoCara Therapeutics Announces Participation in ANESTHESIOLOGY® 2017
finance.yahoo.com - October 17 at 5:42 PM
americanbankingnews.com logoCara Therapeutics, Inc. (CARA) PT Raised to $31.50
www.americanbankingnews.com - October 17 at 2:20 PM
finance.yahoo.com logoCara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus
finance.yahoo.com - October 16 at 5:36 PM
finance.yahoo.com logoCara Therapeutics to Present Data at Kidney Week 2017
finance.yahoo.com - October 16 at 5:36 PM
finance.yahoo.com logoWhere Will Cara Therapeutics Be in 5 Years?
finance.yahoo.com - October 14 at 3:38 AM
thestreet.com logoCommit To Purchase Cara Therapeutics At $10, Earn 25.1% Annualized Using Options - TheStreet.com
www.thestreet.com - October 12 at 5:46 PM
fool.com logoWhere Will Cara Therapeutics Be in 5 Years? - Motley Fool
www.fool.com - October 6 at 5:09 PM
finance.yahoo.com logoCara Therapeutics to Present at the Janney Montgomery Scott Osteoarthritis Pain Conference
finance.yahoo.com - October 5 at 11:53 AM
finance.yahoo.com logoCARA Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CARA-US : October 3, 2017
finance.yahoo.com - October 3 at 4:51 PM
americanbankingnews.com logoCara Therapeutics, Inc. (CARA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 1 at 4:44 AM
americanbankingnews.com logoCara Therapeutics, Inc. (CARA) PT Lowered to $31.00 at Scotiabank
www.americanbankingnews.com - September 28 at 2:28 PM
finance.yahoo.com logoCARA Therapeutics, Inc. – Value Analysis (NASDAQ:CARA) : September 12, 2017
finance.yahoo.com - September 12 at 10:36 PM
fool.com logoHere's Why the Best Is Yet to Come for Cara Therapeutics, Inc. - Motley Fool
www.fool.com - September 11 at 5:33 PM
finance.yahoo.com logoCARA Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CARA-US : September 11, 2017
finance.yahoo.com - September 11 at 5:33 PM
finance.yahoo.com logoHere's Why the Best Is Yet to Come for Cara Therapeutics, Inc.
finance.yahoo.com - September 10 at 4:28 PM
fool.com logoHere's Why the Best Is Yet to Come for Cara Therapeutics, Inc.
www.fool.com - September 10 at 10:10 AM
fool.com logoHere's Why Cara Therapeutics Rose 9.6% in August - Motley Fool
www.fool.com - September 8 at 5:19 PM
finance.yahoo.com logoStocks With Rising Relative Price Strength: Cara Therapeutics
finance.yahoo.com - September 8 at 5:19 PM
finance.yahoo.com logoHere's Why Cara Therapeutics Rose 9.6% in August
finance.yahoo.com - September 7 at 4:39 PM
finance.yahoo.com logoUpcoming Data Releases Fueled Strong Gains in These 2 Marijuana Stocks Last Week
finance.yahoo.com - September 6 at 4:58 PM
finance.yahoo.com logoUpcoming Data Releases Fueled Strong Gains in These 2 Marijuana Stocks Last Week
finance.yahoo.com - September 6 at 4:58 PM
americanbankingnews.com logoCara Therapeutics, Inc. (CARA) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - September 6 at 4:46 AM
nasdaq.com logoSurging Earnings Estimates Signal Good News for Cara Therapeutics (CARA) - Nasdaq
www.nasdaq.com - September 5 at 6:28 PM
finance.yahoo.com logoSurging Earnings Estimates Signal Good News for Cara Therapeutics (CARA)
finance.yahoo.com - September 5 at 6:28 PM
fool.com logoBig Investors Are Buying Cara Therapeutics Stock. Should You? - Motley Fool
www.fool.com - September 1 at 10:11 PM
americanbankingnews.com logoCara Therapeutics, Inc. (NASDAQ:CARA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 12 at 4:32 AM
seekingalpha.com logoCara Therapeutics (CARA) Presents At Canaccord Genuity 37th Annual Growth Conference - Slideshow
seekingalpha.com - August 11 at 5:24 PM
streetinsider.com logoForm SC 13G/A Cara Therapeutics, Inc. Filed by: STATE STREET CORP
www.streetinsider.com - August 11 at 4:08 AM
seekingalpha.com logoA Possible Bump In The Road Ahead For CARA Therapeutics' Lead Drug Candidate, CR845 - Seeking Alpha
seekingalpha.com - August 7 at 10:25 PM
fool.com logo3 Things You Need to Know About Marijuana Stock Cara Therapeutics - Motley Fool
www.fool.com - August 7 at 5:24 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Cara Therapeutics, Inc. and Spectrum Pharmaceuticals
finance.yahoo.com - August 7 at 5:24 PM
americanbankingnews.com logoCara Therapeutics, Inc. (CARA) Given a $25.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - August 6 at 8:56 AM
americanbankingnews.com logoPiper Jaffray Companies Reiterates "$27.00" Price Target for Cara Therapeutics, Inc. (CARA)
www.americanbankingnews.com - August 6 at 8:56 AM
fool.com logoWhy Cara Therapeutics Shares Are Surging 23% Today -- The ... - Motley Fool
www.fool.com - August 5 at 3:17 AM
finance.yahoo.com logoEdited Transcript of CARA earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 5:14 PM
finance.yahoo.com logoEdited Transcript of CARA earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 5:14 PM
finance.yahoo.com logoWhy Cara Therapeutics Shares Are Surging 23% Today
finance.yahoo.com - August 4 at 5:14 PM
finance.yahoo.com logoWhy Cara Therapeutics Shares Are Surging 23% Today
finance.yahoo.com - August 4 at 5:14 PM
americanbankingnews.com logoCara Therapeutics, Inc. (NASDAQ:CARA) Posts Quarterly Earnings Results, Beats Estimates By $0.32 EPS
www.americanbankingnews.com - August 4 at 4:44 PM
americanbankingnews.com logoCara Therapeutics, Inc. (CARA) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - August 4 at 10:08 AM
finance.yahoo.com logoCara Therapeutics to Webcast Presentation at the Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 3 at 6:25 PM
finance.yahoo.com logoCara Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 6:25 PM
finance.yahoo.com logoCara reports 2Q loss
finance.yahoo.com - August 3 at 6:25 PM
americanbankingnews.com logoCara Therapeutics, Inc. (CARA) Price Target Cut to $29.00
www.americanbankingnews.com - August 3 at 3:40 PM
americanbankingnews.com logoCara Therapeutics, Inc. (NASDAQ:CARA) Given New $25.00 Price Target at Raymond James Financial, Inc.
www.americanbankingnews.com - August 3 at 3:40 PM
americanbankingnews.com logoCara Therapeutics, Inc. (NASDAQ:CARA) Price Target Lowered to $32.00 at Scotiabank
www.americanbankingnews.com - August 3 at 3:40 PM

Social

Chart

Cara Therapeutics (CARA) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.